RxDoctor Payments Data

John Yuhas, DO

Internal Medicine · Clyde, OHNPI 1598785842

Payments from drug & device makers

$5,890in general payments, 2019–2025

Across 329 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$921
  • Novo Nordisk$656
  • AstraZeneca$426
  • GSK$290
  • Bayer$279
  • Teva Pharmaceuticals USA, Inc.$274
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,80198%
  • Education$892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,890 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$190,885
Medicare patients
346
Services billed
2,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$142,274
OzempicSemaglutide86$138,012
TrulicityDulaglutide55$108,600
JardianceEmpagliflozin49$64,700
KerendiaFinerenone53$60,950
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$59,575
XareltoRivaroxaban44$58,244
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$56,541
Teriparatide17$45,944
JanuviaSitagliptin Phosphate27$34,420
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$27,564
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$23,519
MounjaroTirzepatide15$23,457
FarxigaDapagliflozin Propanediol14$21,273
Tresiba Flextouch U-200Insulin Degludec23$20,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$656$157,19397 claims
PfizerEliquis$215$142,27497 claims
Lilly USA, LLCTrulicity, Mounjaro$214$132,05770 claims
GSKTrelegy Ellipta, Anoro Ellipta$290$80,06066 claims
Boehringer IngelheimJardiance$161$64,70049 claims
BayerKerendia$279$60,95053 claims
Johnson & JohnsonXarelto$184$58,24444 claims
AstraZenecaBreztri Aerosphere, Farxiga$426$48,83831 claims
MerckJanuvia, Dulera$53$40,43439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Clyde

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →